focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Namibia to start destroying expired vaccines due to slow uptake

Thu, 25th Nov 2021 12:12

By Nyasha Nyaungwa

WINDHOEK, Nov 25 (Reuters) - Namibia has warned that more
than 268,000 doses of AstraZeneca and Pfizer
COVID-19 vaccines are at risk of being destroyed, some as early
as next week, due to a slow uptake by citizens.

Ben Nangombe, executive director in the health ministry,
told Reuters on Thursday that 52,261 AstraZeneca vaccines will
expire on Tuesday next week, while 215,996 Pfizer shots will be
destroyed in January and February if they find no takers as
vaccine hesitancy rises.

Namibia, which has started vaccinating 12- to 17-year olds
with the Pfizer vaccine after the WHO said on Nov. 15 that it is
suitable for people in that age group, has 809,414 doses
available nationally.

The southern African nation recorded 15 new cases on Tuesday
to bring the number of active cases to 85 compared to a peak of
2,547 cases in a single day on June 24.

Only 298,503, or 20% of an estimated eligible population of
1.5 million, have been fully vaccinated in Namibia, with the
Chinese-made Sinopharm vaccine the most used after 145,483
people received two doses since the country’s vaccination
programme started in March.

The Russian-made Sputnik V vaccine has been used the least,
with only 71 people fully vaccinated before its rollout was
suspended on Oct. 23, days after the drugs regulator in
neighbouring South Africa flagged concerns about its safety for
people at risk of HIV.

South African health regulator SAHPRA decided against
approving an emergency use application for Sputnik V after some
studies suggested vaccines using the Adenovirus Type 5 vector -
which Sputnik V does - can lead to higher susceptibility to HIV
in men.

South Africa and Namibia have high HIV prevalence rates.
(Reporting by Nyasha Nyaungwa; editing by Wendell Roelf and
Giles Elgood)

Related Shares

More News
20 May 2024 11:55

LONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes

(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expe...

20 May 2024 08:24

TOP NEWS: AstraZeneca plans to build manufacturing plant in Singapore

(Alliance News) - AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugat...

20 May 2024 07:47

LONDON BRIEFING: Keywords would back GBP2.0 billion bid as EQT circles

(Alliance News) - London's FTSE 100 is called to open higher at the start of the week, while the pound climbed and gold hit another record high, with ...

20 May 2024 07:22

AstraZeneca announces $1.5bn Singapore manufacturing facility

(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of ant...

16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.